Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Radial Approach to Angioplasty Gaining Momentum

Executive Summary

If technology changes and clinical outcomes assert their influence over standard protocols, an increasing number of Americans patients will undergo coronary angioplasty through the radial artery in their wrist, not the femoral artery in their groin. As studies are beginning to portray more clearly, those patients are likely to be more comfortable postprocedure, exhibit less bleeding, and recover more quickly than patients treated treated with the traditional femoral approach.

You may also be interested in...

Interest In Transradial PCI Grows In U.S. But Barriers Remain

The standing-room-only crowd of physicians that packed a meeting room at the recent Transcatheter Cardiovascular Therapeutics conference in San Francisco to hear presentations on transradial percutaneous coronary interventions suggests interest in the technique is growing in the U.S

Valisure’s Benzene Testing Challenged By PCPC; FDA Focus Should Be Raw Materials, Trade Group Says

On roughly the 1-year anniversary of Valisure’s citizen petition to the FDA regarding benzene detected in body sprays, the Personal Care Products Council weighs in on the matter.

CSL’s Hemgenix Gene Therapy Does Not Need A REMS, FDA Tells National Hemophilia Foundation

Peter Marks says labeling for CSL’s hemophilia B treatment adequately conveys its risks. He also denies NHF request that the label cite eligibility criteria used in clinical trials, responding to a citizen petition on the day the agency approves the therapy.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts